About Us
About Us
We create Breakthrough and Disruptive innovations
Vision & Mission
“Detect Earlier. Protect Longer.”
Using blood biomarkers and multimodal data to enable early diagnosis of Alzheimer's and other neurodegenerative diseases, delivering personalized cognitive health solutions.
History
Selected for Ministry of Science and ICT (MSIT) Brain Science Leading Convergence Technology Development Program
Established BRAIN@NUS, Joint Research Center with National University of Singapore (NUS)
Completed Exploratory Clinical Trial for BREDIS DIA P-tau217
Launched Cheetah Care Smart Ring-based Lifelog Digital Healthcare Service
Selected for Full-Cycle R&D IP Solution Support Program
Won Grand Prize, Oh!Ventures Youth Venture Competition Final
Obtained IECEE CB and KC Certification for Cheetah Ring Smart Ring Battery
Registered Cheetah Ring Smart Ring for Conformity of Broadcasting and Communication Equipment (KC Certification)
Reported BREDIS DIA Reader to Ministry of Food and Drug Safety (MFDS) as an In Vitro Diagnostic Medical Device
Won Gyeonggi Regional Small and Medium Business Administration Commissioner's Award, Early-Stage Startup Package (Best Enterprise)
Selected for Seoul Bio & Medical Technology Commercialization Support Program (KRW 400 million, 2 years)
Selected for Ministry of Trade, Industry and Energy (MOTIE) Materials & Components Technology Development Program (KRW 13.5 billion, 5 years)
Selected for Seoul Business Agency (SBA) 2024 Bio-Medical Device Technology Commercialization Support Program
Obtained GMP Certification for In Vitro Diagnostic Medical Device Manufacturing and Quality Control
Designated as GCLP (Good Clinical Laboratory Practice) Institution by the Ministry of Food and Drug Safety (MFDS)
Established Singapore Subsidiary, BREDIS PTE. LTD.
Selected for Korea Credit Guarantee Fund (KODIT) First Penguin Program
Won Grand Prize, Gyeonggi "Change and Opportunity" Startup Competition
Won Korea Forest Service Commissioner's Award, Challenge! K-Startup 2023 Grand Championship
Secured Bridge Investment
Selected as Participating Company, Startup School Busan First-Half Demo Day
Selected for Ministry of SMEs and Startups (MSS) Deep Tech TIPS Program
Selected for 25th POSCO Idea Marketplace
Selected for Healthcare Big Data Platform-based AI Startup Fostering Program
Established In-house R&D Center
Won Korea Women's Enterprise Foundation Chairperson's Award, W-Startup Awards
Won 1st Place, 109th Banks Foundation for Young Entrepreneurs d.camp D-DAY
Selected for Seoul Startup Hub Open Innovation Commercialization Support Program with Large & Mid-sized Enterprises
Secured Seed Investment (3 months after founding)
Registered Domestic Patent for Ultra-Sensitive Biomarker Detection Method
Selected for Gyeonggi-do Digital Innovative Medical Device Development Support Program
Selected for the 15th Cohort of Busan Technology Startup Incubating Support Program (Outstanding Enterprise)
Selected for the 13th Cohort of Korea Credit Guarantee Fund (KODIT) Start-up NEST Program
KAIST Startup Incubating Program
Founded BREDIS Healthcare Co., Ltd.
Leadership
CEO, Bredis Healthcare Inc.
Hyundoo Hwang
“One step closer, every day”
Education
Ph.D. in Bio and Brain Engineering, KAIST
M.S. in Bio and Brain Engineering, KAIST
B.S. in Bio and Brain Engineering, KAIST
Certifications
Alamar Bioscience Certified Service Provider
Bredis Healthcare has been designated as Korea's first official Certified Service Provider (CSP) for Alamar Biosciences' NULISA-based proteomics services. We now deliver world-class, high-precision biomarker analysis and dementia risk prediction directly in Korea, completely eliminating the need for overseas sample shipping.
GCLP Designation
Designated as a clinical trial sample analysis institution certified by the Ministry of Food and Drug Safety (MFDS) in June 2023. We provide highly reliable analysis services, contributing to strengthening the competitiveness of clinical trials in Korea.
Conformity Certification for Manufacturing and Quality Control (GMP) of In Vitro Diagnostic Medical Devices for Clinical Performance Testing
In May 2024, we obtained GMP (Good Manufacturing Practice) certification from the Ministry of Food and Drug Safety (MFDS) for the manufacturing and quality control of in vitro diagnostic medical devices used in clinical performance studies, thereby establishing a quality management system.
IVD Manufacturing Registration
In accordance with Article 5 and Article 11 of the "In Vitro Diagnostic Medical Devices Act," and Article 9 and Article 26 of its Enforcement Rules, we have completed the manufacturing registration for in vitro diagnostic medical devices, and have established a quality and production system based on the relevant regulations.
Institutional Review Board (IRB) Registration Certificate
In accordance with Article 10 of the "Bioethics and Safety Act" and Article 6, Paragraph 3 of its Enforcement Rules, we have completed registration of our Institutional Review Board (IRB), thereby establishing a research framework that meets the ethical and legal standards required for research involving human subjects.
Alamar Bioscience Certified Service Provider
Bredis Healthcare has been designated as Korea's first official Certified Service Provider (CSP) for Alamar Biosciences' NULISA-based proteomics services. We now deliver world-class, high-precision biomarker analysis and dementia risk prediction directly in Korea, completely eliminating the need for overseas sample shipping.
GCLP Designation
Designated as a clinical trial sample analysis institution certified by the Ministry of Food and Drug Safety (MFDS) in June 2023. We provide highly reliable analysis services, contributing to strengthening the competitiveness of clinical trials in Korea.
Conformity Certification for Manufacturing and Quality Control (GMP) of In Vitro Diagnostic Medical Devices for Clinical Performance Testing
In May 2024, we obtained GMP (Good Manufacturing Practice) certification from the Ministry of Food and Drug Safety (MFDS) for the manufacturing and quality control of in vitro diagnostic medical devices used in clinical performance studies, thereby establishing a quality management system.
IVD Manufacturing Registration
In accordance with Article 5 and Article 11 of the "In Vitro Diagnostic Medical Devices Act," and Article 9 and Article 26 of its Enforcement Rules, we have completed the manufacturing registration for in vitro diagnostic medical devices, and have established a quality and production system based on the relevant regulations.
Institutional Review Board (IRB) Registration Certificate
In accordance with Article 10 of the "Bioethics and Safety Act" and Article 6, Paragraph 3 of its Enforcement Rules, we have completed registration of our Institutional Review Board (IRB), thereby establishing a research framework that meets the ethical and legal standards required for research involving human subjects.
Patents
Method for detecting trace analyte particles in fluid samples
Reg. No. 10-2543112
Detection using microparticles for trace analyte analysis
Reg. No. 10-2802232
Microwell microparticle-based detection method
Reg. No. 10-2802234
Automated microneedle analysis device using magnetic stirring elements
Reg. No. 10-2856481
Ultrasensitive Detection Method for Pathogen-Derived Extracellular Vesicles and Uses Thereof
Reg. No. 10-2025-018224
· Multiple international patent applications in progress: Singapore, Japan, China, Europe, USA
Location